• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Osteoarthritis in 2016: Anti-NGF treatments for pain - two steps forward, one step back?

作者信息

Lane Nancy E, Corr Maripat

机构信息

Center for Musculoskeletal Health, Department of Medicine, University of California at Davis School of Medicine, 4625 2nd Avenue, Sacramento, California 95817, USA.

Department of Medicine, University of California at San Diego, 9500 Gilman Drive, La Jolla, California 92093-0663, USA.

出版信息

Nat Rev Rheumatol. 2017 Jan 25;13(2):76-78. doi: 10.1038/nrrheum.2016.224.

DOI:10.1038/nrrheum.2016.224
PMID:28119540
Abstract
摘要

相似文献

1
Osteoarthritis in 2016: Anti-NGF treatments for pain - two steps forward, one step back?2016年骨关节炎：抗神经生长因子治疗疼痛——前进两步，后退一步？
Nat Rev Rheumatol. 2017 Jan 25;13(2):76-78. doi: 10.1038/nrrheum.2016.224.
2
Nerve growth factor blockade for the management of osteoarthritis pain: what can we learn from clinical trials and preclinical models?神经生长因子阻断用于骨关节炎疼痛管理：我们能从临床试验和临床前模型中学到什么？
Curr Opin Rheumatol. 2017 Jan;29(1):110-118. doi: 10.1097/BOR.0000000000000354.
3
The evolution of nerve growth factor inhibition in clinical medicine.神经生长因子抑制作用在临床医学中的演变。
Nat Rev Rheumatol. 2021 Jan;17(1):34-46. doi: 10.1038/s41584-020-00528-4. Epub 2020 Nov 20.
4
Long-term analgesic effect of a single dose of anti-NGF antibody on pain during motion without notable suppression of joint edema and lesion in a rat model of osteoarthritis.单剂量抗神经生长因子抗体对骨关节炎大鼠模型运动时疼痛的长期镇痛作用，且对关节水肿和损伤无明显抑制作用。
Osteoarthritis Cartilage. 2015 Jun;23(6):925-32. doi: 10.1016/j.joca.2015.02.002. Epub 2015 Feb 9.
5
A tale of two TrkA inhibitor trials: same target, divergent results.两项TrkA抑制剂试验的故事：相同靶点，不同结果。
Osteoarthritis Cartilage. 2019 Nov;27(11):1575-1577. doi: 10.1016/j.joca.2019.07.013. Epub 2019 Jul 26.
6
Why are we still using opioids for osteoarthritis?为什么我们还在使用阿片类药物治疗骨关节炎？
Int J Clin Pract. 2020 Jan;74(1):e13416. doi: 10.1111/ijcp.13416. Epub 2019 Oct 23.
7
Blocking the effects of NGF as a route to safe and effective pain relief--fact or fancy?阻断神经生长因子的作用作为安全有效的疼痛缓解途径——事实还是幻想？
Pain. 2011 Oct;152(10):2200-2201. doi: 10.1016/j.pain.2011.06.015. Epub 2011 Jun 29.
8
Efficacy of nerve growth factor antibody in a knee osteoarthritis pain model in mice.神经生长因子抗体在小鼠膝骨关节炎疼痛模型中的疗效
BMC Musculoskelet Disord. 2017 Nov 3;18(1):428. doi: 10.1186/s12891-017-1792-x.
9
Katz et al., efficacy and safety of tanezumab in the treatment of chronic low back pain [Pain 2011;152:2248-2258] and Hill, blocking the effects of NGF as a route to safe and effective pain relief - fact or fancy? [Pain 2011;152:2200-2201].卡茨等人，坦度昔单抗治疗慢性下腰痛的疗效与安全性[《疼痛》2011年；152:2248 - 2258]以及希尔，阻断神经生长因子的作用作为安全有效缓解疼痛的途径——事实还是幻想？[《疼痛》2011年；152:2200 - 2201]
Pain. 2012 May;153(5):1128-1129. doi: 10.1016/j.pain.2012.02.032. Epub 2012 Mar 23.
10
Osteoarthritis in 2010: New takes on treatment and prevention.2010年的骨关节炎：治疗与预防的新进展
Nat Rev Rheumatol. 2011 Feb;7(2):75-6. doi: 10.1038/nrrheum.2010.228.

引用本文的文献

1
Novel insights into the role of ferroptosis in temporomandibular joint osteoarthritis and knee osteoarthritis.铁死亡在颞下颌关节骨关节炎和膝关节骨关节炎中作用的新见解。
Int J Med Sci. 2025 Apr 9;22(9):2119-2131. doi: 10.7150/ijms.107057. eCollection 2025.
2
FM-dye inhibition of Piezo2 relieves acute inflammatory and osteoarthritis knee pain in mice of both sexes.FM 染料对 Piezo2 的抑制可缓解雌雄小鼠的急性炎症性和骨关节炎性膝关节疼痛。
bioRxiv. 2025 Mar 17:2025.03.17.643683. doi: 10.1101/2025.03.17.643683.
3
Pain mediator NGF improves chondrocyte extracellular matrix synthesis via PI3K/AKT pathway.

本文引用的文献

1
Nerve Growth Factor Is Regulated by Toll-Like Receptor 2 in Human Intervertebral Discs.神经生长因子受人类椎间盘内Toll样受体2调控。
J Biol Chem. 2016 Feb 12;291(7):3541-51. doi: 10.1074/jbc.M115.675900. Epub 2015 Dec 14.
2
When Is Osteonecrosis Not Osteonecrosis?: Adjudication of Reported Serious Adverse Joint Events in the Tanezumab Clinical Development Program.当骨坏死不是骨坏死时：替扎尼定在临床试验开发计划中报告的严重关节不良事件的裁决。
Arthritis Rheumatol. 2016 Feb;68(2):382-91. doi: 10.1002/art.39492.
3
A systematic review of the efficacy and general safety of antibodies to NGF in the treatment of OA of the hip or knee.
疼痛介质神经生长因子（NGF）通过PI3K/AKT信号通路改善软骨细胞外基质的合成。
J Orthop Surg Res. 2025 Feb 27;20(1):207. doi: 10.1186/s13018-025-05503-x.
4
Filamented hydrogels as tunable conduits for guiding neurite outgrowth.丝状水凝胶作为引导神经突生长的可调管道。
Mater Today Bio. 2025 Jan 11;31:101471. doi: 10.1016/j.mtbio.2025.101471. eCollection 2025 Apr.
5
Sex-dependent effects of the targeted nerve growth factor mutation (R100E) on pain behavior, joint inflammation, and bone erosion in mice.靶向神经生长因子突变（R100E）对小鼠疼痛行为、关节炎症和骨侵蚀的性别依赖性影响。
Pain. 2024 Dec 1;165(12):2814-2828. doi: 10.1097/j.pain.0000000000003343. Epub 2024 Sep 25.
6
Targeting nerve growth factor for pain relief: pros and cons.以神经生长因子为靶点缓解疼痛：利弊分析
Korean J Pain. 2024 Oct 1;37(4):288-298. doi: 10.3344/kjp.24235. Epub 2024 Sep 26.
7
The challenge of pharmacotherapy for musculoskeletal pain: an overview of unmet needs.肌肉骨骼疼痛药物治疗面临的挑战：未满足需求概述
Ther Adv Musculoskelet Dis. 2024 May 23;16:1759720X241253656. doi: 10.1177/1759720X241253656. eCollection 2024.
8
Targeting aging and age-related diseases with vaccines.用疫苗靶向衰老和与年龄相关的疾病。
Nat Aging. 2024 Apr;4(4):464-482. doi: 10.1038/s43587-024-00597-0. Epub 2024 Apr 15.
9
Recent advances in polymeric microparticle-based drug delivery systems for knee osteoarthritis treatment.用于膝关节骨关节炎治疗的基于聚合物微粒的药物递送系统的最新进展。
Front Bioeng Biotechnol. 2023 Dec 7;11:1290870. doi: 10.3389/fbioe.2023.1290870. eCollection 2023.
10
A Rare Skeletal Disorder, Fibrous Dysplasia: A Review of Its Pathogenesis and Therapeutic Prospects.一种罕见的骨骼疾病，纤维结构不良：发病机制和治疗前景的综述。
Int J Mol Sci. 2023 Oct 26;24(21):15591. doi: 10.3390/ijms242115591.
对神经生长因子抗体治疗髋或膝骨关节炎的疗效和总体安全性的系统评价。
Osteoarthritis Cartilage. 2015 Jan;23 Suppl 1:S8-17. doi: 10.1016/j.joca.2014.10.003.
4
Nerve growth factor downregulates inflammatory response in human monocytes through TrkA.神经生长因子通过 TrkA 下调人单核细胞的炎症反应。
J Immunol. 2014 Apr 1;192(7):3345-54. doi: 10.4049/jimmunol.1300825. Epub 2014 Feb 28.
5
Structural, biological, and pharmacological strategies for the inhibition of nerve growth factor.神经生长因子抑制的结构、生物学和药理学策略。
Neurochem Int. 2012 Dec;61(8):1266-75. doi: 10.1016/j.neuint.2012.10.008. Epub 2012 Oct 26.
6
Tanezumab for the treatment of pain from osteoarthritis of the knee.特耐珠单抗治疗膝骨关节炎疼痛。
N Engl J Med. 2010 Oct 14;363(16):1521-31. doi: 10.1056/NEJMoa0901510. Epub 2010 Sep 29.
7
Nerve growth factor promotes TLR4 signaling-induced maturation of human dendritic cells in vitro through inducible p75NTR 1.神经生长因子通过诱导性p75神经营养因子受体1在体外促进Toll样受体4信号诱导的人树突状细胞成熟。
J Immunol. 2007 Nov 1;179(9):6297-304. doi: 10.4049/jimmunol.179.9.6297.
8
TLR2 is required for the altered transcription of p75NGF receptors in gram positive infection.
Neurochem Res. 2006 Feb;31(2):297-301. doi: 10.1007/s11064-005-9020-8. Epub 2006 Mar 3.